Physician profile
Bryan E Martin
NPI 1689786519
$1,052.19
in general payments reported to CMS, 2019-2025
21 companies · $201 in 2025
The $201 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2020: $12.00 · 2021: $103 · 2022: $264 · 2023: $120 · 2024: $219 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $462 · Education: $77.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $461.50 |
| Education | $77.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $151.52 | 2019-2024 | Padcev, Xospata |
| Amgen INC. | $128.96 | 2019-2023 | Blincyto, Kyprolis |
| E.R. Squibb & Sons, L.L.C. | $117.26 | 2019-2023 | Sprycel |
| Celgene Corporation | $95.33 | 2022-2025 | Reblozyl, Sprycel |
| Novartis Pharmaceuticals Corporation | $79.89 | 2019-2024 | |
| Abbvie INC. | $73.44 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $63.49 | 2019-2025 | Keytruda, Welireg |
| Genentech, INC. | $53.45 | 2025 | Tecentriq |
| Janssen Biotech, INC. | $46.28 | 2024-2025 | Akeega, Balversa, Erleada |
| Gilead Sciences, INC. | $41.46 | 2021-2024 | |
| Pfizer INC. | $30.20 | 2023-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $26.64 | 2021-2023 | Imbruvica |
| Eisai INC. | $20.77 | 2024 | |
| Incyte Corporation | $18.71 | 2024 | Jakafi |
| Beone Medicines USA, INC. | $17.37 | 2025 | Brukinsa |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adaptive Biotechnologies Corporation | $16.00 | 2022 | |
| Alnylam Pharmaceuticals INC. | $15.98 | 2024 | Amvuttra |
| Springworks Therapeutics, INC. | $15.64 | 2025 | Gomekli |
| Acrotech Biopharma INC. | $15.20 | 2025 | Beleodaq |
| Regeneron Healthcare Solutions, INC. | $13.12 | 2024 | Libtayo |
| Astrazeneca Pharmaceuticals Lp | $11.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.